WO2002028362A3 - Composition vaccinale et procede de stabilisation - Google Patents

Composition vaccinale et procede de stabilisation Download PDF

Info

Publication number
WO2002028362A3
WO2002028362A3 PCT/FR2001/003097 FR0103097W WO0228362A3 WO 2002028362 A3 WO2002028362 A3 WO 2002028362A3 FR 0103097 W FR0103097 W FR 0103097W WO 0228362 A3 WO0228362 A3 WO 0228362A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine composition
stabilisation
stabilisation method
vaccine
albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/003097
Other languages
English (en)
Other versions
WO2002028362A2 (fr
Inventor
Alain Francon
Catherine Noel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccines US Inc
Original Assignee
Aventis Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/381,948 priority Critical patent/US6982088B2/en
Priority to CA002424863A priority patent/CA2424863A1/fr
Priority to KR1020037004927A priority patent/KR100832551B1/ko
Priority to JP2002531988A priority patent/JP2004526667A/ja
Priority to AU2001295672A priority patent/AU2001295672B2/en
Priority to AU9567201A priority patent/AU9567201A/xx
Priority to NZ525117A priority patent/NZ525117A/en
Priority to EP01976379A priority patent/EP1357895A2/fr
Application filed by Aventis Pasteur Inc filed Critical Aventis Pasteur Inc
Priority to MXPA03002875A priority patent/MXPA03002875A/es
Priority to BR0114350-6A priority patent/BR0114350A/pt
Publication of WO2002028362A2 publication Critical patent/WO2002028362A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002028362A3 publication Critical patent/WO2002028362A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention est relative à la stabilisation de composition vaccinale maintenue à l'état liquide grâce à l'utilisation de polyvinylpyrrolidone de haut poids moléculaire, ce qui permet de s'affranchir de l'utilisation d'albumine. Cette invention est d'un intérêt particulier pour les compositions vaccinales comprenant des virus vivants atténués, tels que le vaccin oral contre la poliomyélite.
PCT/FR2001/003097 2000-10-06 2001-10-08 Composition vaccinale et procede de stabilisation Ceased WO2002028362A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NZ525117A NZ525117A (en) 2000-10-06 2001-10-08 Vaccine composition stabilised by addition of high-molecular-weight polyvinylpyrrolidone, in particular PVF360 whose molecular weight is 360 000 daltons
KR1020037004927A KR100832551B1 (ko) 2000-10-06 2001-10-08 백신 조성물 및 안정화 방법
JP2002531988A JP2004526667A (ja) 2000-10-06 2001-10-08 ワクチン組成物および安定化方法
AU2001295672A AU2001295672B2 (en) 2000-10-06 2001-10-08 Vaccine composition and stabilisation method
AU9567201A AU9567201A (en) 2000-10-06 2001-10-08 Vaccine composition and stabilisation method
US10/381,948 US6982088B2 (en) 2000-10-06 2001-10-08 Vaccine composition and stabilization method using high molecular weight PVP
BR0114350-6A BR0114350A (pt) 2000-10-06 2001-10-08 Composição vacinal e processo de estabilização da mesma no estado lìquido
EP01976379A EP1357895A2 (fr) 2000-10-06 2001-10-08 Composition vaccinale et procede de stabilisation
MXPA03002875A MXPA03002875A (es) 2000-10-06 2001-10-08 Composicion de vacuna y metodo de estabilizacion.
CA002424863A CA2424863A1 (fr) 2000-10-06 2001-10-08 Composition vaccinale et procede de stabilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012805A FR2814957B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale et procede de stabilisation
FR00/12805 2000-10-06

Publications (2)

Publication Number Publication Date
WO2002028362A2 WO2002028362A2 (fr) 2002-04-11
WO2002028362A3 true WO2002028362A3 (fr) 2003-09-12

Family

ID=8855080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003097 Ceased WO2002028362A2 (fr) 2000-10-06 2001-10-08 Composition vaccinale et procede de stabilisation

Country Status (12)

Country Link
US (1) US6982088B2 (fr)
EP (1) EP1357895A2 (fr)
JP (1) JP2004526667A (fr)
KR (1) KR100832551B1 (fr)
CN (1) CN1298387C (fr)
AU (2) AU2001295672B2 (fr)
BR (1) BR0114350A (fr)
CA (1) CA2424863A1 (fr)
FR (1) FR2814957B1 (fr)
MX (1) MXPA03002875A (fr)
NZ (1) NZ525117A (fr)
WO (1) WO2002028362A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
RU2639526C2 (ru) 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
SMT201900520T1 (it) 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
US10137186B2 (en) * 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
NL2018155B1 (en) * 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
AU2020368656A1 (en) * 2019-10-16 2022-04-21 Janssen Vaccines & Prevention B.V. Vaccine product
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1588829A (fr) * 1967-06-22 1970-03-16
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
EP0273512A2 (fr) * 1986-12-19 1988-07-06 Duphar International Research B.V Suspension adjuvante stabilisée comprenant du bromure de diméthyl dioctadécyl ammonium
WO1994015636A1 (fr) * 1993-01-08 1994-07-21 Csl Limited Preparations de vaccins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915764A (en) * 1973-05-18 1975-10-28 Westinghouse Electric Corp Sputtering method for growth of thin uniform layers of epitaxial semiconductive materials doped with impurities
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
CA2158935A1 (fr) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Procedes de conservation de virus de recombinaison
US6379677B1 (en) * 2000-02-25 2002-04-30 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Streptococcus iniae vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1588829A (fr) * 1967-06-22 1970-03-16
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
EP0273512A2 (fr) * 1986-12-19 1988-07-06 Duphar International Research B.V Suspension adjuvante stabilisée comprenant du bromure de diméthyl dioctadécyl ammonium
WO1994015636A1 (fr) * 1993-01-08 1994-07-21 Csl Limited Preparations de vaccins

Also Published As

Publication number Publication date
JP2004526667A (ja) 2004-09-02
AU9567201A (en) 2002-04-15
CN1298387C (zh) 2007-02-07
EP1357895A2 (fr) 2003-11-05
US20030190331A1 (en) 2003-10-09
CA2424863A1 (fr) 2002-04-11
FR2814957B1 (fr) 2002-12-20
WO2002028362A2 (fr) 2002-04-11
KR20030096223A (ko) 2003-12-24
US6982088B2 (en) 2006-01-03
NZ525117A (en) 2006-08-31
CN1468091A (zh) 2004-01-14
BR0114350A (pt) 2004-02-17
FR2814957A1 (fr) 2002-04-12
KR100832551B1 (ko) 2008-05-26
AU2001295672B2 (en) 2005-08-18
MXPA03002875A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
WO2002009746A8 (fr) Composition vaccinale
EP1245668A3 (fr) Composition nettoyante
WO2002080965A3 (fr) Composition vaccinale
WO2002062380A3 (fr) Composition vaccinale
HUP0402179A3 (en) Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
IL114641A0 (en) Pharmaceutical compositions containing fluoxetine
WO2002007742A3 (fr) Bacteriophage a spectre d'activite multiple
WO2002060926A3 (fr) Inhibiteurs du virus de l'hepatite c
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
WO2003061555A3 (fr) Vacccin west nile
CA2420874A1 (fr) Combinaisons de principes actifs a proprietes insecticides et acaricides
AU2001277961A1 (en) Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
CA2241464A1 (fr) Combinaison de nisine et de monolaurate de glycerol agissante contre helicobacter
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
WO2002096936A3 (fr) Daptomycine et analogues s'y rapportant, sous forme cristalline
WO2002102345A3 (fr) Deferoxamine comme inhibiteur de no-synthase et utilisations
PL344851A1 (en) Bacterium of salmonella type and vaccine containing that bacterium for protecting animals against salmonellosis and method of obtaining such vaccine
WO2004085682A3 (fr) Utilisation de substances actives pour la prevention ou le traitement de maladies virales, et systeme de test pour la recherche de telles substances actives
WO2002013855A3 (fr) Vaccins contenant de la ribavirine et procedes d'utilisation associes
EP1570067A4 (fr) Methodes et compositions d'immunisation contre le virus vih
WO2000067741A3 (fr) Methodes et compositions de formoterol (s,r)
WO2001078787A3 (fr) Vaccin conjugue anti-sepsie
PL342624A1 (en) Derivatives of streptogramines, method of obtaining them and compositions containing such derivatives
WO2005011571A3 (fr) Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10381948

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001295672

Country of ref document: AU

Ref document number: PA/a/2003/002875

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 525117

Country of ref document: NZ

Ref document number: 463/CHENP/2003

Country of ref document: IN

Ref document number: 2003/00426

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2424863

Country of ref document: CA

Ref document number: 2002531988

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037004927

Country of ref document: KR

Ref document number: 018169708

Country of ref document: CN

Ref document number: 2001976379

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001976379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037004927

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001295672

Country of ref document: AU